120 related articles for article (PubMed ID: 21400510)
1. Brain-derived neurotrophic factor is a potential osteoclast stimulating factor in multiple myeloma.
Sun CY; Chu ZB; She XM; Zhang L; Chen L; Ai LS; Hu Y
Int J Cancer; 2012 Feb; 130(4):827-36. PubMed ID: 21400510
[TBL] [Abstract][Full Text] [Related]
2. Gene silencing of the BDNF/TrkB axis in multiple myeloma blocks bone destruction and tumor burden in vitro and in vivo.
Ai LS; Sun CY; Wang YD; Zhang L; Chu ZB; Qin Y; Gao F; Yan H; Guo T; Chen L; Yang D; Hu Y
Int J Cancer; 2013 Sep; 133(5):1074-84. PubMed ID: 23420490
[TBL] [Abstract][Full Text] [Related]
3. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
Giuliani N; Colla S; Rizzoli V
Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
[TBL] [Abstract][Full Text] [Related]
4. Identification of brain-derived neurotrophic factor as a novel angiogenic protein in multiple myeloma.
Hu Y; Wang YD; Guo T; Wei WN; Sun CY; Zhang L; Huang J
Cancer Genet Cytogenet; 2007 Oct; 178(1):1-10. PubMed ID: 17889702
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
Zannettino AC; Farrugia AN; Kortesidis A; Manavis J; To LB; Martin SK; Diamond P; Tamamura H; Lapidot T; Fujii N; Gronthos S
Cancer Res; 2005 Mar; 65(5):1700-9. PubMed ID: 15753365
[TBL] [Abstract][Full Text] [Related]
6. [Expression and significance of brain-derived neurotrophic factors and receptors in multiple myeloma].
Sun CY; Hu Y; Wu T; Wang YD; He WJ
Zhonghua Nei Ke Za Zhi; 2005 Dec; 44(12):906-9. PubMed ID: 16409727
[TBL] [Abstract][Full Text] [Related]
7. [Mechanisms for formation of myeloma bone disease].
Yata K; Abe M; Matsumoto T
Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
[TBL] [Abstract][Full Text] [Related]
8. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
9. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
[TBL] [Abstract][Full Text] [Related]
10. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
11. [Study of brain-derived neurotrophic factor activating TrkB signaling cascades in the pathogenesis of multiple myeloma].
Sun CY; Hu Y; Guo T; Huang J; Zhang L; Chu ZB
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):238-42. PubMed ID: 18843977
[TBL] [Abstract][Full Text] [Related]
12. BDNF and its TrkB receptor in human fracture healing.
Kilian O; Hartmann S; Dongowski N; Karnati S; Baumgart-Vogt E; Härtel FV; Noll T; Schnettler R; Lips KS
Ann Anat; 2014 Sep; 196(5):286-95. PubMed ID: 24984919
[TBL] [Abstract][Full Text] [Related]
13. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
[TBL] [Abstract][Full Text] [Related]
14. Brain-derived neurotrophic factor promotes growth and migration of multiple myeloma cells.
Hu Y; Sun CY; Wang HF; Guo T; Wei WN; Wang YD; He WJ; Wu T; Tan H; Wu TC
Cancer Genet Cytogenet; 2006 Aug; 169(1):12-20. PubMed ID: 16875931
[TBL] [Abstract][Full Text] [Related]
15. [Bone disease in multiple myeloma and its mechanism].
Abe M
Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
17. Evidence of a role for RANKL in the development of myeloma bone disease.
De Leenheer E; Mueller GS; Vanderkerken K; Croucher PI
Curr Opin Pharmacol; 2004 Aug; 4(4):340-6. PubMed ID: 15251126
[TBL] [Abstract][Full Text] [Related]
18. An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors.
Zannettino AC; Farrugia AN; To LB; Atkins GJ
Methods Mol Med; 2005; 113():245-56. PubMed ID: 15968108
[TBL] [Abstract][Full Text] [Related]
19. The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma.
Bataille R; Chappard D; Klein B
Int J Clin Lab Res; 1992; 21(4):283-7. PubMed ID: 1591381
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib inhibits human osteoclastogenesis.
von Metzler I; Krebbel H; Hecht M; Manz RA; Fleissner C; Mieth M; Kaiser M; Jakob C; Sterz J; Kleeberg L; Heider U; Sezer O
Leukemia; 2007 Sep; 21(9):2025-34. PubMed ID: 17581612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]